Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy

We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug conjugates used clinically as cancer treatments. While providing both efficacy and favorable tolerability, ADCs have limitatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindberg, Jakob, Nilvebrant, Johan, Nygren, Per-Åke, Lehmann, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512983/
https://www.ncbi.nlm.nih.gov/pubmed/34641586
http://dx.doi.org/10.3390/molecules26196042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512983/
https://www.ncbi.nlm.nih.gov/pubmed/34641586
http://dx.doi.org/10.3390/molecules26196042

Ejemplares similares